Primary Outcome Measures:
- Adverse effect rates [ Time Frame: Ongoing ] [ Designated as safety issue: Yes ]
- Clinical status as indicated by NYHA functional classification [ Time Frame: At required follow-up visits ] [ Designated as safety issue: No ]
- Hemodynamic performance [ Time Frame: At required follow-up visits ] [ Designated as safety issue: No ]
Intervention Details:
Device: EPIC
Surgical replacement of a diseased, damaged, or malfunctioning native or prosthetic aortic and/or mitral heart valves
This study is a multi-centered, multi-country, prospective, non-randomized, observational study, without concurrent or matched controls, conducted under a common protocol. Bayesian methods will be used for the design and analysis of this study. The Bayesian model will determine if the data for the valve configurations are poolable. Bayesian methods also provide a means of determining the appropriate stopping time for the study based on the amount of information generated. The objectives of this study are to confirm the clinical safety and efficacy of the SJM Epic Valve by establishing the following:
- adverse effect rates
- clinical status as indicated by NYHA functional classification
- hemodynamic performance